推荐产品
应用
VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human is a homodimeric protein contains extracellular domain of human VEGF R2 (KDR) fused to the 6x histidine tagged Fc portion of human IgG1 by the peptide (EGF). The product was used to stuyd vasculogenesis and angiogenesis and as marker for pluripotent hematopoietic stem cells.
生化/生理作用
VEGF Receptor-2 (VEGF R2) also known as Flk-1 or KDR belongs to class III subfamily of RTKs is a potent VEGF antagonist and is mainly expressed in endothelial cells. VEGF R2 can stimulate PLC-gamma pathway which in turn activate MAP kinase and subsequent strong signalling as well as can partly induces mitotic signals in NIH3T3 fibroblasts. KDR also facilitates the release of nitric oxide in endothelial cells and assist in the regulation of the vasculature.
VEGF receptors, class III receptor tyrosine kinases, have seven Ig like extracellular motifs and a tyrosine kinase intracellular domain split by a kinase insert sequence. VEGFR 1 and 2 are both expressed in an endothelial cell-specific manner.
外形
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin.
分析说明
The biological activity is measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Science (New York, N.Y.), 285(5433), 1553-1558 (1999-09-08)
Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial
Biochemical and biophysical research communications, 265(3), 636-639 (1999-12-22)
VEGF-A induces angiogenesis and regulates endothelial function via production and release of nitric oxide (NO), which is produced by endothelial nitric oxide synthase (eNOS). While the upregulation of eNOS expression has been shown to be mediated via VEGF receptor KDR
Vaccine, 35(28), 3582-3590 (2017-05-26)
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported
Oncogene, 14(17), 2079-2089 (1997-05-01)
KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood. Here we examined the processing and
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门